Minireview: Dynamic structures of nuclear hormone receptors: New promises and challenges

Molecular Endocrinology

Volumn 28, Issue 2, 2014, Pages 173-182

  Simons, S Stoney ^a   Edwards, Dean P ^b   Kumar, Raj ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c PA Professor of Surgery Department of Clinical Sciences The Geisinger Commonwealth Medical College Scranton   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION FUNCTION 1 PROTEIN; CELL NUCLEUS RECEPTOR; INTRINSICALLY DISORDERED PROTEIN; PROTEIN; UNCLASSIFIED DRUG; CELL RECEPTOR;

ALLOSTERISM; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATOR GENE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ALLOSTERIC REGULATION; ANIMALS; HUMANS; INTRINSICALLY DISORDERED PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTIONAL ACTIVATION;

EID: 84892495900     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1334     Document Type: Review

References (93)

1. Kumar R, McEwan IJ. Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev. 2012;33(2):271-299.
2. Nilsson S, Koehler KF, Gustafsson J Å. Development of subtypeselective oestrogen receptor-based therapeutics. Nat Rev Drug Discov. 2011;10(10):778-792.
3. McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol. 2010;10(6):620-628.
4. Shapiro DJ, Mao C, Cherian MT. Small molecule inhibitors as probes for estrogen and androgen receptor action. J Biol Chem. 2011;286(6):4043-4048.
5. Johnson AB, O'Malley BW. Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol. 2012;348(2):430-439.
6. Huang W, Greene GL, Ravikumar KM, Yang S. Cross-talk between the ligand-and DNA-binding domains of estrogen receptor. Proteins. 2013;81(11):1909-1919.
7. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389(6652):753-758.
8. Wu YL, Yang X, Ren Z, et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell. 2005;18(4): 413-424.
9. Nettles KW, Bruning JB, Gil G, et al. Structural plasticity in the oestrogen receptor ligand-binding domain. EMBO Rep. 2007;8(6): 563-568.
10. Hollenberg SM, Evans RM. Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell. 1988;55(5):899-906.
11. Onate SA, Boonyaratanakornkit V, Spencer TE, et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem. 1998;273(20):12101-12108.
12. Kitagawa H, Yanagisawa J, Fuse H, et al. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol. 2002;22(11):3698-3706.
13. Liu J, Perumal NB, Oldfield CJ, Su EW, Uversky VN, Dunker AK. Intrinsic disorder in transcription factors. Biochemistry. 2006;45(22):6873-6888.
14. Dunker AK, Uversky VN. Drugs for 'protein clouds': targeting intrinsically disordered transcription factors. Curr Opin Pharmacol. 2010;10(6):782-788.
15. Ferreon AC, Ferreon JC, Wright PE, Deniz AA. Modulation of allostery by protein intrinsic disorder. Nature. 2013;498(7454): 390-394.
16. Demarest SJ, Martinez-Yamout M, Chung J, et al. Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature. 2002;415(6871):549-553.
17. Vacic V, Oldfield CJ, Mohan A, et al. Characterization of molecular recognition features, MoRFs, and their binding partners. J Proteome Res. 2007;6(6):2351-2366.
18. Dunker AK, Uversky VN. Signal transduction via unstructured protein conduits. Nat Chem Biol. 2008;4(4):229-230.
19. Wright PE, Dyson HJ. Linking folding and binding. Curr Opin Struct Biol. 2009;19(1):31-38.
20. Fischer K, Kelly SM, Watt K, Price NC, McEwan IJ. Conformation of the mineralocorticoid receptor N-terminal domain: evidence for induced and stable structure. Mol Endocrinol. 2010;24(10):1935-1948.
21. Kumar R, Lee JC, Bolen DW, Thompson EB. The conformation of the glucocorticoid receptor af1/tau1 domain induced by osmolyte binds co-regulatory proteins. J Biol Chem. 2001;276(21):18146-18152.
22. Bain DL, Franden MA, McManaman JL, Takimoto GS, Horwitz KB. The N-terminal region of human progesterone B-receptors: biophysical and biochemical comparison to A-receptors. J Biol Chem. 2001;276(26):23825-23831.
23. Wärnmark A, Wikström A, Wright AP, Gustafsson JA, Härd T. The N-terminal regions of estrogen receptor α and β are unstructured in vitro and show different TBP binding properties. J Biol Chem. 2001;276(49):45939-45944.
24. Reid J, Kelly SM, Watt K, Price NC, McEwan IJ. Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation. Influence of structure-stabilizing solutes and protein-protein interactions. J Biol Chem. 2002;277(22):20079-20086.
25. Khan SH, Awasthi S, Guo C, et al. Binding of the N-terminal region of coactivator TIF2 to the intrinsically disordered AF1 domain of the glucocorticoid receptor is accompanied by conformational reorganizations. J Biol Chem. 2012;287(53):44546-44560.
26. Chalmers MJ, Busby SA, Pascal BD, et al. Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2006;78(4):1005-1014.
27. Bruning JB, Chalmers MJ, Prasad S, et al. Partial agonists activate PPARγ using a helix 12 independent mechanism. Structure. 2007;15(10):1258-1271.
28. Chandra V, Huang P, Hamuro Y, et al. Structure of the intact PPAR-γ-RXR-nuclear receptor complex on DNA. Nature. 2008; 456(7220):350-356.
29. Kumar R, Moure CM, Khan SH, et al. Regulation of the structurally dynamic amino-terminal domain of progesterone receptor by protein induced folding. J Biol Chem. 2013.
30. Lonard DM, O'Malley BW. Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol. 2012;8(10):598-604.
31. Chen W, Rogatsky I, Garabedian MJ. MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol Endocrinol. 2006;20(3):560-572.
32. Choudhry MA, Ball A, McEwan IJ. The role of the general transcription factor IIF in androgen receptor-dependent transcription. Mol Endocrinol. 2006;20(9):2052-2061.
33. Motlagh HN, Hilser VJ. Agonism/antagonism switching in allosteric ensembles. Proc Natl Acad Sci USA. 2012;109(11):4134-4139.
34. Khan SH, Ling J, Kumar R. TBP binding-induced folding of the glucocorticoid receptor AF1 domain facilitates its interaction with steroid receptor coactivator-1. PLoS One. 2011;6(7):e21939.
35. Kumar R, Volk DE, Li J, Lee JC, Gorenstein DG, Thompson EB. TATA box binding protein induces structure in the recombinant glucocorticoid receptor AF1 domain. Proc Natl Acad Sci USA. 2004;101(47):16425-16430.
36. Kumar R, Betney R, Li J, Thompson EB, McEwan IJ. Induced alpha-helix structure in AF1 of the androgen receptor upon binding transcription factor TFIIF. Biochemistry. 2004;43(11):3008-3013.
37. Ma H, Hong H, Huang SM, et al. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol. 1999;19(9):6164-6173.
38. Wang D, Simons SS Jr. Corepressor binding to progesterone and glucocorticoid receptors involves the activation function-1 domain and is inhibited by molybdate. Mol Endocrinol. 2005;19(6):1483-1500.
39. Cho S, Blackford JA Jr, Simons SS Jr. Role of activation function domain-1, DNA binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid receptor-antagonist complexes. Biochemistry. 2005;44(9):3547-3561.
40. Hill KK, Roemer SC, Churchill ME, Edwards DP. Structural and functional analysis of domains of the progesterone receptor. Mol Cell Endocrinol. 2012;348(2):418-429.
41. Garza AM, Khan SH, Kumar R. Site-specific phosphorylation induces functionally active conformation in the intrinsically disordered N-terminal activation function (AF1) domain of the glucocorticoid receptor. Mol Cell Biol. 2010;30(1):220-230.
42. Chandra V, Huang P, Potluri N, Wu D, Kim Y, Rastinejad F. Multidomain integration in the structure of the HNF-4α nuclear receptor complex. Nature. 2013;495(7441):394-398.
43. Whitford PC. Disorder guides protein function. Proc Natl Acad Sci USA. 2013;110(18):7114-7115.
44. Wardell SE, Kwok SC, Sherman L, Hodges RS, Edwards DP. Regulation of the amino-terminal transcription activation domain of progesterone receptor by a cofactor-induced protein folding mechanism. Mol Cell Biol. 2005;25(20):8792-8808.
45. Hill KK, Roemer SC, Jones DN, Churchill ME, Edwards DP. A progesterone receptor co-activator (JDP2) mediates activity through interaction with residues in the carboxyl-terminal extension of the DNA binding domain. J Biol Chem. 2009;284(36): 24415-24424.
46. Garza AS, Khan SH, Moure CM, Edwards DP, Kumar R. Bindingfolding induced regulation of AF1 transactivation domain of the glucocorticoid receptor by a cofactor that binds to its DNA binding domain. PLoS One. 2011;6(10):e25875.
47. Watson LC, Kuchenbecker KM, Schiller BJ, Gross JD, Pufall MA, Yamamoto KR. The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. Nat Struct Mol Biol. 2013;20(7):876-883.
48. Brodie J, McEwan IJ. Intra-domain communication between the N-terminal and DNA-binding domains of the androgen receptor: modulation of androgen response element DNA binding. J Mol Endocrinol. 2005;34(3):603-615.
49. Kumar R, Baskakov IV, Srinivasan G, Bolen DW, Lee JC, Thompson EB. Interdomain signaling in a two-domain fragment of the human glucocorticoid receptor. J Biol Chem. 1999;274(35): 24737-24741.
50. Meijsing SH, Pufall MA, So AY, Bates DL, Chen L, Yamamoto KR. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 2009;324(5925):407-410.
51. Rochel N, Ciesielski F, Godet J, et al. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat Struct Mol Biol. 2011;18(5):564-570.
52. Osz J, Pethoukhov MV, Sirigu S, Svergun DI, Moras D, Rochel N. Solution structures of PPARγ2/RXRα complexes. PPAR Res. 2012;2012:701412.
53. Orlov I, Rochel N, Moras D, Klaholz BP. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J. 2012;31(2):291-300.
54. Dai SY, Chalmers MJ, Bruning J, et al. Prediction of the tissuespecificity of selective estrogen receptor modulators by using a single biochemical method. Proc Natl Acad Sci USA. 2008;105(20): 7171-7176.
55. Zhang J, Chalmers MJ, Stayrook KR, et al. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol. 2011;18(5):556-563.
56. Devarakonda S, Gupta K, Chalmers MJ, et al. Disorder-to-order transition underlies the structural basis for the assembly of a transcriptionally active PGC-1α/ERRγ complex. Proc Natl Acad Sci USA. 2011;108(46):18678-18683.
57. Wang Q, Blackford JA Jr, Song LN, Huang Y, Cho S, Simons SS Jr. Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors. Mol Endocrinol. 2004;18(6):1376-1395.
58. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990;9(9):2811-2818.
59. Simons SS Jr. Glucocorticoid receptor cofactors as therapeutic targets. Curr Opin Pharmacol. 2010;10(6):613-619.
60. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science. 1994;264(5164): 1455-1458.
61. Szapary D, Huang Y, Simons SS Jr. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol Endocrinol. 1999;13(12): 2108-2121.
62. Lee GS, Simons SS Jr. Ligand binding domain mutations of the glucocorticoid receptor selectively modify the effects with, but not binding of, cofactors. Biochemistry. 2011;50(3):356-366.
63. Norris JD, Paige LA, Christensen DJ, et al. Peptide antagonists of the human estrogen receptor. Science. 1999;285(5428):744-746.
64. Sistare FD, Hager GL, Simons SS Jr. Mechanism of dexamethasone 21-mesylate antiglucocorticoid action: I. Receptor-antiglucocorticoid complexes do not competitively inhibit receptor-glucocorticoid complex activation of gene transcription in vivo. Mol Endocrinol. 1987;1(9):648-658.
65. Billas I, Moras D. Allosteric controls of nuclear receptor function in the regulation of transcription. J Mol Biol. 2013;425(13):2317-2329.
66. Estébanez-Perpiñá E, Arnold LA, Arnold AA, et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci USA. 2007;104(41):16074-16079.
67. Joseph JD, Wittmann BM, Dwyer MA, et al. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc Natl Acad Sci USA. 2009;106(29):12178-12183.
68. Norris JD, Joseph JD, Sherk AB, et al. Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands. Chem Biol. 2009;16(4): 452-460.
69. Simons SS, Jr, Chow CC. The road less traveled: new views of steroid receptor action from the path of dose-response curves. Mol Cell Endocrinol. 2012;348(2):373-382.
70. Ong KM, Blackford JA, Jr, Kagan BL, Simons SS, Jr, Chow CC. A theoretical framework for gene induction and experimental comparisons. Proc Natl Acad Sci USA. 2010;107(15):7107-7112.
71. Luo M, Simons SS Jr. Modulation of glucocorticoid receptor induction properties by cofactors in peripheral blood mononuclear cells. Hum Immunol. 2009;70(10):785-789.
72. Awasthi S, Simons SS Jr. Separate regions of glucocorticoid receptor, coactivator TIF2, and comodulator STAMP modify different parameters of glucocorticoid-mediated gene induction. Mol Cell Endocrinol. 2012;355(1):121-134.
73. Dougherty EJ, Guo C, Simons SS Jr, Chow CC. Deducing the temporal order of cofactor function in ligand-regulated gene transcription: theory and experimental verification. PLoS One. 2012;7(1): e30225.
74. Blackford JA Jr, Guo C, Zhu R, Dougherty EJ, Chow CC, Simons SS Jr. Identification of location and kinetically defined mechanism of cofactors and reporter genes in the cascade of steroid-regulated transactivation. J Biol Chem. 2012;287(49):40982-40995.
75. Zhang Z, Sun Y, Cho YW, Chow CC, Simons SS Jr. PA1 protein, a new competitive decelerator acting at more than one step to impede glucocorticoid receptor-mediated transactivation. J Biol Chem. 2013;288(1):42-58.
76. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998;95(7):927-937.
77. Reese JC, Katzenellenbogen BS. Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res. 1991;19(23):6595-6602.
78. Cheng J, Zhang C, Shapiro DJ. A functional serine 118 phosphorylation site in estrogen receptor-α is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxytamoxifen. Endocrinology. 2007;148(10):4634-4641.
79. Johnston SJ, Cheung KL. Fulvestrant-a novel endocrine therapy for breast cancer. Curr Med Chem. 2010;17(10):902-914.
80. Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol. 2011;82(2):122-130.
81. Robertson JF. Fulvestrant (Faslodex)-how to make a good drug better. Oncologist. 2007;12(7):774-784.
82. Wardell SE, Nelson ER, Chao CA, McDonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res. 2013;19(9):2420-2431.
83. Kretzer NM, Cherian MT, Mao C, et al. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor α. J Biol Chem. 2010;285(53):41863-41873.
84. Jones JO, Bolton EC, Huang Y, et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA. 2009;106(17):7233-7238.
85. Mao C, Patterson NM, Cherian MT, et al. A new small molecule inhibitor of estrogen receptor α binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem. 2008;283(19):12819-12830.
86. Arnal JF, Fontaine C, Abot A, et al. Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor α in vivo. Steroids. 2013;78(6):576-582.
87. Arao Y, Hamilton KJ, Goulding EH, Janardhan KS, Eddy EM, Korach KS. Transactivating function (AF) 2-mediated AF-1 activity of estrogen receptor α is crucial to maintain male reproductive tract function. Proc Natl Acad Sci USA. 2012;109(51):21140-21145.
88. Arao Y, Hamilton KJ, Ray MK, Scott G, Mishina Y, Korach KS. Estrogen receptor α AF-2 mutation results in antagonist reversal and reveals tissue selective function of estrogen receptor modulators. Proc Natl Acad Sci USA. 2011;108(36):14986-14991.
89. Billon-Galés A, Fontaine C, Filipe C, et al. The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17β-estradiol. Proc Natl Acad Sci USA. 2009;106(6):2053-2058.
90. Börjesson AE, Windahl SH, Lagerquist MK, et al. Roles of transactivating functions 1 and 2 of estrogen receptor-α in bone. Proc Natl Acad Sci USA. 2011;108(15):6288-6293.
91. Billon-Galés A, Krust A, Fontaine C, et al. Activation function 2 (AF2) of estrogen receptor-α is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc Natl Acad Sci USA. 2011;108(32):13311-13316.
92. Andersen RJ, Mawji NR, Wang J, et al. Regression of castraterecurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010;17(6):535-546.
93. Myung JK, Banuelos CA, Fernandez JG, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013;123(7):2948-2960.